About XenoPort, Inc.
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
|
|
|
51-200 employees
View all XenoPort, Inc. employees
|
|
Pharmaceuticals
|
|
United States
|
|
1999
|
XenoPort, Inc. Alternatives
Frequently Asked Questions about XenoPort, Inc.
Jessica Nancy is the CEO of XenoPort, Inc.. To contact Jessica Nancy email at [email protected].
XenoPort, Inc. Staff Directory
Search XenoPort, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
